Ultrasound-Guided Glenohumeral Steroid Injection
Primary Purpose
Adhesive Capsulitis of Shoulder
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Glenohumeral triamcinolone injection by anterior approach
Glenohumeral triamcinolone injection by posterior approach
Sponsored by
About this trial
This is an interventional treatment trial for Adhesive Capsulitis of Shoulder
Eligibility Criteria
Inclusion Criteria:
- shoulder pain and limitations of active and passive motion in at least two directions (abduction and forward flexion < 100, external rotation < 30, or internal rotation < L3) on the pre-injection check-up
- those who underwent MRI or ultrasonography with no secondary cause for adhesive capsulitis, such as a rotator cuff tear, calcific tendinitis, or osteoarthritis
Exclusion Criteria:
- history of fracture or operation on the affected shoulder
- loss to follow-up before 13 weeks after the injection
- receiving another treatment that was different from our protocol within 13 weeks after the injection
- no functional scores within 13 weeks after the injection
Sites / Locations
- Chuncheon Sacred Heart Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
anterior approach
posterior approach
Arm Description
Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Outcomes
Primary Outcome Measures
visual analog scale (VAS) for pain
0-10, 0: no pain, 10: very severe pain
range of motion (ROM)
degree
patient's satisfaction (SAT)
0-10, 0: not satisfied, 10: very much satisfied
American Shoulder and Elbow Surgeons (ASES) shoulder score
0-100
Constant score
0-100
Secondary Outcome Measures
Accuracy of injection using post-injection X-ray
Injection material includes 3cc Omnipaque, therefore, the accuracy of injection can be checked just after the injection. After the injection, anteroposterior, scapular lateral, and axillary x-rays of the shoulder were taken of all patients within 15 min, and leakage was classified into three categories by a musculoskeletal radiologist with 18 years experience: 1) no leakage; 2) leakage; and 3) cannot be determined.
Full Information
NCT ID
NCT02461368
First Posted
May 29, 2015
Last Updated
September 20, 2023
Sponsor
Chuncheon Sacred Heart Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02461368
Brief Title
Ultrasound-Guided Glenohumeral Steroid Injection
Official Title
Comparison Between Anterior and Posterior Approaches for Ultrasound-guided Glenohumeral Steroid Injection: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
February 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chuncheon Sacred Heart Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators compared the results of the ultrasound-guided anterior and posterior approaches to administer glenohumeral steroid injections to patients with primary adhesive capsulitis of the shoulder joint by a single experienced provider.
Detailed Description
This study was a randomized controlled trial of 50 patients, who underwent history taking, physical examinations, x-rays, and MRI or ultrasonography, and were diagnosed with primary adhesive capsulitis of the shoulder from December 2012 to November 2013. The 50 patients were assigned to Group I (anterior approach) or Group II (posterior approach) under double-blinded randomization. The randomization was performed by an independent nurse using a computerized random sequence generator. The operators who participated in the procedure were blinded to the participant's information. The injection mixture for both groups was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare). After the injection, anteroposterior, scapular lateral, and axillary x-rays of the shoulder were taken of all patients within 15 min, and leakage was classified into three categories by a musculoskeletal radiologist with 18 years experience: 1) no leakage; 2) leakage; and 3) cannot be determined. Injection accuracy was defined as [number of 1) ÷ {number of 1) + number of 2) + number of 3)}] × 100 (%). The frequency of needling until the injection had been completed was checked. A visual analog scale (VAS) for pain, range of motion (ROM), patient's satisfaction (SAT), the American Shoulder and Elbow Surgeons (ASES) shoulder score, and the Constant score were recorded before, and 3, 7, and 13 weeks after the injection. VAS scores range from 0 to 10, with 0 being no pain and 10 being the most severe pain ever experienced. Internal rotation was measured from buttock to T5 in this study, with the range between L5 and T5 being allocated a sequential value between 2 and 13 and the range below the first sacral vertebra being allocated 1. SAT was also selected from a scale of 0 to 10, with 0 being unsatisfactory and 10 being very satisfactory. Stick exercises were started at 3 weeks, and theraband exercises were started 7 weeks after the injection.
Two patients of 54 patients who had been assessed for eligibility in this study were excluded due to proximal humerus fractures of the affected shoulders. And another two participants were excluded because they had declined to participate. One Group I patient was excluded due to an additional subacromial injection 3 weeks after the study injection. And another Group I patient was excluded due to loss of follow-up before 13 weeks. Also, two patients were excluded from Group II because of loss to follow-up. Finally, 46 patients were included in the study (n = 23/group). The demographic data of the two groups were not significantly different.
Diagnostic ultrasonography was performed by a musculoskeletal radiologist with 18 years experience using ultrasound (Philips Healthcare) before the injection. The ultrasound-guided glenohumeral steroid injection was administered by a shoulder and elbow surgeon who performed more than 2,000 similar procedures.
A 21-gauge spinal needle was used for all of the ultrasound-guided steroid injections. The patient was supine with the shoulder slightly rotated externally for the anterior approach. The shoulder was draped in sterile fashion using 70% alcohol and povidone-iodine solution. The linear ultrasonography probe (General Electronics Healthcare) was prepared with 70% alcohol and a thin layer of sterile ultrasonographic transmission gel (Republic of Korea). The needle was inserted at the level of the coracoids, from lateral to medial, and was aimed at the medial border of the humeral head, parallel to the longitudinal axis of the probe. The posterior approach was performed with the patient in the lateral decubitus position on the unaffected side, leaning 45 degree anteriorly and hugging a pillow. The needle was inserted from lateral to medial, parallel to the longitudinal axis of the probe, and into the joint between the humeral head and the posterior glenoid labrum.
The participants took off their coats and shirts in the injection room. Females wore a skirt at the axillary level exposing the shoulder for injection. The provider entered the injection room and positioned the patients appropriately. Just after positioning, the operator put on gloves, prepared the injection mixture, and administered the injection. Positioning time (from operator entering the room until the end of positioning) and injection time (from putting on gloves until just after the injection) were recorded by an independent nurse. The sum of the two times was recorded as the total time, and the frequency of needling during the injection for one patient was also recorded.
A power analysis indicated that a sample size of 46 patients (23/group) would provide a statistical power of 80%, with a two-sided α level of 0.05 to detect a significant difference in the improvement of ASES score between initial and 13 weeks after injection, assuming an effect size of 0.85 (mean difference, 16.1; standard deviation, 19.0). This was based on the mean and standard deviation of the improvement of ASES score between initial and 13 weeks after injection observed in a pilot study of 20 patients.
The Wilcoxon signed-rank test was used to compare preoperative and postoperative data. Normally distributed data between the groups were analyzed using the independent sample t-test. Otherwise, the nonparametric Mann-Whitney U-test was used. Statistical analyses were performed with SPSS ver. 13.0 software (SPSS Inc., Chicago, USA). A p value < 0.05 was considered statistically significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adhesive Capsulitis of Shoulder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
anterior approach
Arm Type
Experimental
Arm Description
Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Arm Title
posterior approach
Arm Type
Active Comparator
Arm Description
Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Intervention Type
Procedure
Intervention Name(s)
Glenohumeral triamcinolone injection by anterior approach
Intervention Description
Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Intervention Type
Procedure
Intervention Name(s)
Glenohumeral triamcinolone injection by posterior approach
Intervention Description
Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Primary Outcome Measure Information:
Title
visual analog scale (VAS) for pain
Description
0-10, 0: no pain, 10: very severe pain
Time Frame
initial, Week 3, 7, 13
Title
range of motion (ROM)
Description
degree
Time Frame
initial, Week 3, 7, 13
Title
patient's satisfaction (SAT)
Description
0-10, 0: not satisfied, 10: very much satisfied
Time Frame
initial, Week 3, 7, 13
Title
American Shoulder and Elbow Surgeons (ASES) shoulder score
Description
0-100
Time Frame
initial, Week 3, 7, 13
Title
Constant score
Description
0-100
Time Frame
initial, Week 3, 7, 13
Secondary Outcome Measure Information:
Title
Accuracy of injection using post-injection X-ray
Description
Injection material includes 3cc Omnipaque, therefore, the accuracy of injection can be checked just after the injection. After the injection, anteroposterior, scapular lateral, and axillary x-rays of the shoulder were taken of all patients within 15 min, and leakage was classified into three categories by a musculoskeletal radiologist with 18 years experience: 1) no leakage; 2) leakage; and 3) cannot be determined.
Time Frame
within 15 minutes after injection
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
shoulder pain and limitations of active and passive motion in at least two directions (abduction and forward flexion < 100, external rotation < 30, or internal rotation < L3) on the pre-injection check-up
those who underwent MRI or ultrasonography with no secondary cause for adhesive capsulitis, such as a rotator cuff tear, calcific tendinitis, or osteoarthritis
Exclusion Criteria:
history of fracture or operation on the affected shoulder
loss to follow-up before 13 weeks after the injection
receiving another treatment that was different from our protocol within 13 weeks after the injection
no functional scores within 13 weeks after the injection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jung-Taek Hwang, MD, PhD
Organizational Affiliation
Chuncheon Sacred Heart Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chuncheon Sacred Heart Hospital
City
Chuncheon
State/Province
Gangwon-do
ZIP/Postal Code
700-204
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Ultrasound-Guided Glenohumeral Steroid Injection
We'll reach out to this number within 24 hrs